A randomized phase I/II trial of hyperfractionated radiation therapy with total doses of 60.0 Gy to 79.3 Gy: possible survival benefit with greater than or equal to 69.6 Gy in favorable patients with Radiation Therapy Oncology Group stage III non-small-cell lung carcinoma: report of Radiation Therapy Oncology Group 83 - 11. - Cox,J.; Azarnia,N.; Byhardt,R.W.; Shin,K.H.; Emami,B.; Pajak,T.F. (J Clin Oncol, 1990)